HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial

Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination

(2014) N. L. Yates et al.   Science Translational Medicine

Broad and Potent Cellular and Humoral Immune Responses After a Second Late HIV-Modified Vaccinia Virus Ankara Vaccination in HIV-DNA-Primed and HIV-Modified Vaccinia Virus Ankara-Boosted Swedish Vaccinees

(2013) Charlotta Nilsson et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

(2013) Spyros A. Kalams et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Immunogenicity of DNA and MVA HIV-1 Subtype C Vaccine Prime-Boost Regimens: A Phase I Randomised Trial in HIV-Uninfected Indian Volunteers

(2013) Sanjay Mehendale et al.   PLoS One

Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial

(2013) Raphael Gottardo et al.   PLoS One

Novel directions in HIV-1 vaccines revealed from clinical trials

(2013) Jean-Louis Excler et al.   Current Opinion in HIV and AIDS

The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope

(2012) M. S. de Souza et al.   JOURNAL OF IMMUNOLOGY

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

(2012) Dan H. Barouch et al.   NATURE

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial

(2012) Barton F. Haynes et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques

(2012) Rashmi Jalah et al.   Human Vaccines & Immunotherapeutics

Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles

(2011) Paul A. Goepfert et al.   JOURNAL OF INFECTIOUS DISEASES

In Vivo Electroporation Enhances the Immunogenicity of an HIV-1 DNA Vaccine Candidate in Healthy Volunteers

(2011) Sandhya Vasan et al.   PLoS One

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial

(2011) Beryl A. Koblin et al.   PLoS One

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)

(2011) Gavin J. Churchyard et al.   PLoS One

Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania

(2011) Muhammad Bakari et al.   VACCINE

Strong HIV-Specific CD4+ and CD8+ T-Lymphocyte Proliferative Responses in Healthy Individuals Immunized with an HIV-1 DNA Vaccine and Boosted with Recombinant Modified Vaccinia Virus Ankara Expressing HIV-1 Genes

(2010) S. Aboud et al.   Clinical and Vaccine Immunology

CD8+T-cell-mediated control of HIV-1 and SIV infection

(2010) Stephanie A. Freel et al.   IMMUNOLOGIC RESEARCH

A Phase 1/2 Study of a Multiclade HIV‐1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV‐Uninfected East Africans (RV 172)

(2010) Hannah Kibuuka et al.   JOURNAL OF INFECTIOUS DISEASES

Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses

(2010) Richard A. Koup et al.   PLoS One

HIV vaccines: lessons learned and the way forward

(2010) Jerome H Kim et al.   Current Opinion in HIV and AIDS

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

International Network for Comparison of HIV Neutralization Assays: The NeutNet Report

(2009) Eva Maria Fenyö et al.   PLoS One

Skin Electroporation: Effects on Transgene Expression, DNA Persistence and Local Tissue Environment

(2009) Anna-Karin Roos et al.   PLoS One

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

(2009) Patricia L. Earl et al.   VACCINE

Optimal Blood Mononuclear Cell Isolation Procedures for Gamma Interferon Enzyme-Linked Immunospot Testing of Healthy Swedish and Tanzanian Subjects

(2008) C. Nilsson et al.   Clinical and Vaccine Immunology

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

(2008) Alexandre Harari et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Broad Immunogenicity of a Multigene, Multiclade HIV‐1 DNA Vaccine Boosted with Heterologous HIV‐1 Recombinant Modified Vaccinia Virus Ankara

(2008) Eric Sandström et al.   JOURNAL OF INFECTIOUS DISEASES

Recruitment of Antigen-Presenting Cells to the Site of Inoculation and Augmentation of Human Immunodeficiency Virus Type 1 DNA Vaccine Immunogenicity by In Vivo Electroporation

(2008) J. Liu et al.   JOURNAL OF VIROLOGY

Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation

(2008) Margherita Rosati et al.   VACCINE

Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques

(2007) Lauren A. Hirao et al.   VACCINE